ArriVent BioPharma (AVBP) Interest & Investment Income (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Interest & Investment Income data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income rose 17.02% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (down 10.16% YoY), and the FY2025 full-year result was $11.2 million, down 18.77% from the prior year.
• Interest & Investment Income eased to $2.8 million in Q1 2026, from $3.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $3.8 million in Q2 2024 to a low of $1.0 million in Q2 2023.
• A 4-year average of $2.8 million and a median of $2.9 million in 2024 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income jumped 275.91% in 2024 and sank 41.83% in 2025, its largest moves.
• Tracing AVBP's Interest & Investment Income over 4 years: stood at $1.9 million in 2023, then jumped by 59.58% to $3.1 million in 2024, then grew by 6.74% to $3.3 million in 2025, then fell by 14.88% to $2.8 million in 2026.
• Business Quant data shows AVBP's Interest & Investment Income at $2.8 million in Q1 2026, $3.3 million in Q4 2025, and $3.3 million in Q3 2025.